Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifenprodil
- Development stage
- Phase 3
- Lead developer
- Seyltx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ifenprodil is a small molecule cerebral vasodilator and non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, with selectivity for receptors containing the GluN2B subunit. It also inhibits G protein-activated inwardly rectifying potassium (GIRK) channels and interacts with α1-adrenergic, serotonin, and sigma receptors. Ifenprodil has been marketed in some countries for cerebral vasodilation and dizziness after brain ischemia. It is under investigation for additional indications including neuroprotection, anti-inflammatory effects (notably in viral-induced lung injury), substance use disorders such as methamphetamine dependence and alcohol dependence, as well as COVID-19. Its mechanism involves modulation of glutamatergic neurotransmission via NMDA receptor antagonism[1][2][3][6].
- Brand names
- CerocralDilvaxVadilex
- Other names
- ifenprodil tartrate
02
Targets
ADRA1A (α1A)GIRK (G protein-coupled inward-rectifier potassium channel)5-HT (Serotonin receptors)σR (Sigma receptors)KACh (G protein–activated inwardly rectifying potassium channel)GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)
Beyond the preview
Go deeper on ifenprodil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifenprodil.